Stocktoria
Imunon, Inc. IMNN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 1993-10-27
Imunon, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $500,000 | $500,000 |
| R&D expense | $7.8M | $11.6M | $11.3M | $11.7M | $10.6M |
| Operating income | -$14.7M | -$19.1M | -$21.0M | -$24.9M | -$21.0M |
| Interest expense | — | — | $197,080 | $5.0M | $569,881 |
| Income tax | — | — | -$1.3M | -$1.6M | -$1.4M |
| Net income | -$14.5M | -$18.6M | -$19.5M | -$35.9M | -$20.8M |
| EPS (diluted) | $-6.83 | $-16.94 | $-2.16 | $-5.03 | — |
| Operating cash flow | -$13.9M | -$18.9M | -$19.0M | -$23.1M | -$16.2M |
| Free cash flow | -$14.2M | -$18.9M | -$19.5M | -$23.4M | -$16.5M |
| Cash & equivalents | $8.8M | $5.9M | $5.8M | $11.5M | $19.6M |
| Total assets | $12.3M | $9.7M | $21.9M | $44.0M | $74.0M |
| Total liabilities | $5.2M | $5.5M | $8.5M | $14.6M | $18.3M |
| Shareholders' equity | $7.1M | $4.2M | $13.4M | $29.3M | $55.8M |
Source: SEC EDGAR filings · CIK 0000749647 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.